On-Demand Webinar: Standardizing Endpoints Today. Forecasting Progression Tomorrow

‍

Standardizing Endpoints Today. Forecasting Progression Tomorrow.

Ophthalmic drug development heavily relies on two critical pillars most clinical trials still struggle to deliver: standardizing imaging data across multiple sites and accurately predicting which patients will progress and when.

In this strategic and technical session, you will discover how RetinAI bridges these gaps using a comprehensive, end-to-end AI pipeline:‍

• RetinAI Discovery® & OCT Atlas® (CE-marked under MDR): A device-agnostic solution that automates layer, fluid, and biomarker segmentation across Diabetic Retinopathy, Glaucoma, and AMD, validated against expert graders in the DILL study.
• GA Progression Prediction Model (RUO): A research-only predictive layer built on top of our certified foundation, capable of forecasting outer retina atrophy up to 4 years ahead, even in early-stage patients with small lesions.

What will you learn: 

• Device-Agnostic, Standardized Quantification: Learn how RetinAI OCT Atlas® delivers consistent automated segmentation across Heidelberg, Topcon, Zeiss, and other major OCT platforms, eliminating hardware constraints and manual normalization.
• The DILL Study Validation: Review the data showing how our automated analysis met all literature-defined performance targets for critical biomarkers against three independent expert graders, in under one second per scan.
• Forecasting GA Progression Up to 4 Years: Understand the mechanics of the research layer (RUO) that forecasts outer retina atrophy across critical layers (ONL+HFL, MZ, EZ+OPR+IZ, and RPE) to optimize trial design and patient selection.

Who will benefit from this session: 

• Pharma & Biotech Clinical Operations Teams: Who need to deliver standardized biomarker endpoints across every single site in a trial without dealing with hardware fragmentation.
• Ophthalmology Data Scientists & Innovation Leaders: Interested in leveraging validated predictive modeling to optimize patient selection and protocol designs for Geographic Atrophy (GA) trials.‍
• Clinical Researchers & Retina Specialists: Seeking to understand the state-of-the-art AI applications for automated, multi-disease quantification in AMD, Glaucoma, and DR.

‍

‍

Meet the speakers: 

• David Romero-Bascones – Research Engineer at RetinAI
• Guilherme Moreira Aresta – Research Engineer at RetinAI
• Natasa Jovic – VP Marketing Strategy & Research Partnerships at RetinAI